Etanercept biosimilar - Pfizer

Drug Profile

Etanercept biosimilar - Pfizer

Alternative Names: Lifmior

Latest Information Update: 30 Dec 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis

Most Recent Events

  • 15 Dec 2016 Preregistration for Ankylosing spondylitis in European Union (SC)
  • 15 Dec 2016 Preregistration for Juvenile rheumatoid arthritis in European Union (SC)
  • 15 Dec 2016 Preregistration for Plaque psoriasis (In children, In adolescents) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top